StockWatch
·

Syngene International Ltd Q2 FY27 Results

SYNGENEQ2 FY27 Results
Filing
Result:Weak· Market: Surged#One-off hit#Margin squeeze

Beat/Miss: Beat

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue832.7013.1%8.6%
Total Income860.7013.1%7.0%
Expenditure807.005.2%4.0%
PBT47.00344.8%44.8%
Net Profit32.20457.8%52.0%
OPM16.90%6.40pp5.01pp
NPM3.74%4.92pp3.51pp
EPS0.80263.6%52.1%
View full financials

Core revenue fell 8.6% YoY and adjusted PAT still dropped ~45% YoY on margin compression, so despite beating the Street/pre-result range and a sequential recovery from Q1's loss, the YoY core-metric decline caps this below-par for the sector.

Q2 FY-2027 RESULTS · SYNGENE

Syngene Q2 FY27: PAT -52% YoY to ₹32 Cr as margin rebounds off Q1's low

PAT -52.01% YoY · revenue -8.55% · margins compressing · beat vs street

27 Oct 2026 · 3 min read
Revenue

₹832.7 Cr

-8.55% YoY

PAT (consolidated)

₹32.2 Cr

-52.01% YoY

Net margin

3.74%

-3.5pp YoY

EPS

₹0.8

Syngene's consolidated revenue came in at ₹832.7 Cr, down 8.6% YoY from ₹910.6 Cr but up 13.1% sequentially from Q1's ₹736.0 Cr. Consolidated PAT of ₹32.2 Cr fell 52% YoY from ₹67.1 Cr, though it marks a clear sequential turnaround from Q1's ₹9 Cr net loss. The quarter carried a ₹6.7 Cr exceptional charge for employee termination benefits (Note 7) against none in the year-ago quarter; stripping it out, adjusted PAT is roughly ₹36.8 Cr, still down ~45% YoY. Standalone PAT of ₹48.7 Cr (EPS ₹1.21) diverges meaningfully from consolidated PAT of ₹32.2 Cr (EPS ₹0.80) — the ~₹16 Cr gap reflects losses/consolidation drag at the US and manufacturing subsidiaries, a materially different picture between the two bases worth flagging.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹832.7 Cr+13.1%-8.6%
Expenses₹807 Cr+5.2%-4%
PAT₹32.2 Cr—-52.01%
Net margin3.74%+4.9pp-3.5pp
EPS₹0.8+263.6%-52.1%

Operating margin (EBITDA/revenue, computed) recovered sharply to ~21.1% this quarter from ~10.5% in Q1, closing most of the gap to the year-ago 21.9% OPM — tangible evidence that cost actions taken after Q1's biologics-contract loss are working. Net margin, however, stayed compressed at 3.9% versus 7.25% a year ago on the smaller revenue base. Finance costs (₹10.0 Cr) and depreciation (₹111.7 Cr) stayed elevated, consistent with continuing capex — consolidated capital work-in-progress rose to ₹1,140.6 Cr from ₹1,040.4 Cr at FY26-end.

₹
337.81358.97380.13401.28422.44366.207-2408-1709-0810-0110-27Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹366.2, down 3.7% over the past month of trading.

₹ Cr
-27.8337.02101.88166.7386.7Q1 FY26rev ₹875 Cr67.1Q2 FY26rev ₹911 Cr16.5Q3 FY26rev ₹834 Cr147.9Q4 FY26rev ₹1,037 Cr-9Q1 FY27rev ₹736 Cr32.2Q2 FY27rev ₹833 Cr
Quarterly consolidated PAT, ₹ Crore
What management guided (1 FY-2027 call)
FY27 single-digit revenue decline in rupees (revised from flat); EBITDA margins mid-20s maintained; H1 weak, H2 stronger; FY28 return to profitable growth expected.

— This quarter: met

Against the ~₹700-750 Cr revenue range flagged in our pre-result preview, the ₹832.7 Cr print is a clear beat; the Street's FY27 EPS consensus of ₹9.90 implied expectations of stabilization, which this quarter's swing back to profit supports, though the YoY profit decline shows the recovery isn't complete. Management's prior guidance (Q1 FY27 call) called for a single-digit FY27 revenue decline, mid-20s EBITDA margins, and a weak H1 with a stronger H2; H1 FY27 consolidated revenue of ₹1,568.7 Cr is down 12.1% YoY from ₹1,785.1 Cr, steeper than the guided full-year decline but consistent with management's own framing that H1 would be the weak half. Margin at 21.1% this quarter remains short of the guided mid-20s band but is trending toward it, so guidance looks on track rather than missed or beaten outright. The quarter also saw continued leadership churn — Head of Corporate Affairs resigned September 21, 2026, following director Kush Parmar's July 29, 2026 exit — alongside the ongoing voluntary liquidation of subsidiary Syngene Manufacturing Solutions (initiated June 15, 2026). No management press release commentary was available to cross-check against the filing.

  • W1

    H2 FY27 revenue must outperform H1's -12.1% YoY decline for the full year to land within management's guided single-digit decline

  • W2

    EBITDA margin path toward management's mid-20s FY27 target from this quarter's ~21.1%

  • W3

    Completion status of Syngene Manufacturing Solutions' voluntary liquidation, ongoing as of September 30, 2026

Current quarter carries a ₹6.7 Cr exceptional charge (employee termination benefits, Note 7) vs no exceptional item in Q2 FY26; prior quarter (Q1 FY27) had a larger ₹13.5 Cr exceptional charge. PDF is clean/digital, all tables legible, arithmetic ties out on both bases.

Informational and educational content only. Not investment advice.